ArticleDrug and alcohol review2026
Exploring Age and Sex Differences in the Use of Cannabis Vaping Products: Results From the Canadian Cannabis Survey 2020-2023.
Article in Drug and alcohol review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction to "Exploring Age and Sex Differences in the Use of Cannabis Vaping Products: Results From the Canadian Cannabis Survey 2020-2023".Drug and alcohol review · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
introductionUse of cannabis vaping products has been increasing in Canada. This study examined the prevalence and patterns of use of cannabis vaping products, including higher-risk use, by sex and age.
methodsData were from four cycles of the Canadian Cannabis Survey, an annual web-based survey of people aged ≥ 16 years in Canada. Past 12-month consumers of cannabis for non-medical purposes were analysed (n
resultsAmong past 12 month cannabis consumers, use of cannabis vaping products in the past 12 months increased from 22% (95% CI 20%-23%) in 2020 to 37% (95% CI 35%-39%) in 2023, with increases in all sex and age categories, most notably youth (16-19 years) whose use doubled from 33% (95% CI 27%-38%) to 66% (95% CI 60%-72%). Daily/almost daily use of cannabis vaping products also increased overall, from 2% (95% CI 1%-2%) in 2020 to 6% (95% CI 5%-7%) in 2023. There were few sex differences in patterns of use. The proportion of vaping product consumers classified as low risk increased from 13% (95% CI 10.3-16.6) in 2020 to 22% (95% CI 19.1-24.7) in 2023. The proportion classified as high risk also increased, while the proportion classified as moderate risk decreased. DISCUSSION AND
conclusionsFollowing legalization (2020 to 2023), there was a continued increase in the use of cannabis vaping products, especially among youth. Continued monitoring as well as additional public education efforts, especially related to potency and risks of vaping, are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.